EUVIMEDEUVIMED entdecken
FallberichtOpen Access

IL ‐17 Signaling Inhibitors in Localized Scleroderma: A Single‐Center Case Series of Nine Patients

Takuya Takahashi iD, Takehiro Takahashi iD, Yuichiro Segawa iD, Kenta Oka iD, Toshiya Takahashi iD, Yoshihide Asano iD

The Journal of Dermatology · 2026

DOI: 10.1111/1346-8138.70390 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Takuya Takahashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Interleukin-17, Scleroderma, Localized, Receptors, Interleukin-17. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Localized scleroderma (LSc) is an autoimmune fibrosing disorder characterized by inflammation and sclerosis of the skin and underlying soft tissues. IL‐17 signaling has been implicated in active inflammatory lesions, but treatment options for severe or refractory LSc remain limited. Here, we present nine patients with LSc treated with IL‐17A or IL‐17 receptor A inhibitors at our institution (ixekizumab, secukinumab, or brodalumab). These biologics were administered to patients refractory to conventional therapies or anticipated to have treatment‐resistant disease, following institutional approval for unapproved drug use. Five patients improved, two stabilized, and two progressed. One patient developed pustulotic arthro‐osteitis during brodalumab treatment, possibly representing a paradoxical reaction; no other major adverse events were observed. Although these uncontrolled retrospective data do not establish efficacy, they suggest that IL‐17 pathway inhibition merits further study in selected patients with refractory LSc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-17Scleroderma, LocalizedReceptors, Interleukin-17HumansFemaleAntibodies, Monoclonal, HumanizedMaleMiddle AgedAdultAntibodies, MonoclonalSignal TransductionTreatment OutcomeRetrospective StudiesAgedSkin

Stichwörter der Autor:innen

IL‐17AIL‐17RAbrodalumabixekizumablocalized sclerodermasecukinumab

Substanzen

Interleukin-17Antibodies, Monoclonal, HumanizedsecukinumabixekizumabbrodalumabAntibodies, MonoclonalReceptors, Interleukin-17IL17A protein, humanIL17RA protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

ORCID-Profile: Takuya Takahashi, Takehiro Takahashi, Yuichiro Segawa, Kenta Oka, Toshiya Takahashi, Yoshihide Asano

Zitieren

APA

Takahashi, T., Takahashi, T., Segawa, Y., Oka, K., Takahashi, T., & Asano, Y. (2026). IL ‐17 Signaling Inhibitors in Localized Scleroderma: A Single‐Center Case Series of Nine Patients. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70390

Vancouver

Takahashi T, Takahashi T, Segawa Y, Oka K, Takahashi T, Asano Y. IL ‐17 Signaling Inhibitors in Localized Scleroderma: A Single‐Center Case Series of Nine Patients. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70390

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Takuya and Takahashi, Takehiro and Segawa, Yuichiro and Oka, Kenta and Takahashi, Toshiya and Asano, Yoshihide},
  title = {IL ‐17 Signaling Inhibitors in Localized Scleroderma: A Single‐Center Case Series of Nine Patients},
  journal = {The Journal of Dermatology},
  year = {2026},
  doi = {10.1111/1346-8138.70390}
}
Kostenlos starten →